Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of KHK4083 induction and extension therapy in moderately active ulcerative colitis
2015-001555-69Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing KHK4083 with Placebo (2 arms). Primary endpoint: Change in modified Mayo endoscopic subscore. Started Nov 2015; status: completed.
02
Drugs
rocatinlimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-001555-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001555-69.